{"entity":{"id":"nct05065801","kind":"trial","name":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","aka":["GABRINOX2"],"tldr":"A phase 2 trial in pancreatic cancer, run by Institut du Cancer de Montpellier - Val d'Aurelle, now recruiting.","summary":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients is a phase 2, randomised interventional study registered as NCT05065801 by Institut du Cancer de Montpellier - Val d'Aurelle, with a registry enrolment figure of 162 participants, started 2022-01-11 and due to reach its primary completion in 2026-12-30. Interventions recorded: GEMBRAX/FOLFIRINOX Arm A; FOLFIRINOX Arm B. Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Progression-free survival. Pancreatic eligibility wording from the registry: \"Histologically or cytologically proven metastatic pancreatic adenocarcinoma\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05065801","url":"https://clinicaltrials.gov/study/NCT05065801"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05065801","phase":"2","setting":"Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","participation":[{"nct":"NCT05065801","source":"https://clinicaltrials.gov/study/NCT05065801","fetchedAt":"2026-10-07T16:53:33.387Z","studySha256":"7c41eec124d4c1130cde2d84794015e9c3dda980ff77c55a44b2cb40693d1124","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-15","leadSponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":162,"enrolmentType":"ESTIMATED","siteCount":8,"recruitingSiteCount":5,"countries":["France"]}],"started":"2022-01-11","startedType":"actual","enrolled":162,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05065801/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}